Atrial Natriuretic Peptide (ANP), also known as Atrial Natriuretic Factor (ANF) or atriopeptin, is a 28-amino acid peptide hormone primarily synthesized and stored in granules within atrial cardiomyocytes. First described by de Bold et al. in 1981, ANP was the founding member of the natriuretic peptide family — a discovery that fundamentally changed understanding of the heart as an endocrine organ.

Overview

ANP is synthesized as a 151-amino acid preproANP, which is stored in atrial granules as the 126-amino acid proANP. Upon secretion, the transmembrane serine protease corin cleaves proANP into the biologically active 28-amino acid alpha-ANP (amino acids 99-126) and the inactive N-terminal proANP fragment (NT-proANP, amino acids 1-98). ANP contains a 17-amino acid ring structure formed by an intramolecular disulfide bond between Cys7 and Cys23, which is essential for biological activity.

ANP exerts its effects primarily through natriuretic peptide receptor A (NPR-A, also called GC-A), a transmembrane guanylyl cyclase receptor. Receptor activation increases intracellular cGMP, triggering vasodilation, natriuresis, diuresis, and inhibition of the renin-angiotensin-aldosterone system (RAAS). ANP is cleared rapidly from circulation by natriuretic peptide receptor C (NPR-C) and enzymatic degradation by neprilysin, resulting in a very short plasma half-life of 2-5 minutes.

Carperitide (hanp, hANP) is a recombinant form of human ANP approved in Japan since 1995 for the treatment of acute heart failure. It has been used extensively in Japanese clinical practice, though it has not received regulatory approval in Western countries, where nesiritide (recombinant BNP) was the analogous therapeutic agent.

Mechanism of Action

ANP activates multiple coordinated pathways to reduce blood volume and blood pressure:

NPR-A/cGMP Signaling: ANP binds to natriuretic peptide receptor A (NPR-A/GC-A) on vascular smooth muscle cells, renal epithelial cells, adrenal cells, and other target tissues. NPR-A is a single-pass transmembrane receptor with an extracellular ligand-binding domain and an intracellular guanylyl cyclase domain. ANP binding activates particulate guanylyl cyclase, increasing intracellular cGMP, which activates protein kinase G (PKG), cGMP-gated ion channels, and cGMP-regulated phosphodiesterases.

Vasodilation and Preload Reduction: ANP-mediated cGMP/PKG signaling in vascular smooth muscle reduces intracellular calcium levels through inhibition of calcium channels and activation of calcium-ATPases, producing arterial and venous dilation. Venodilation reduces cardiac preload, while arteriolar dilation reduces afterload and systemic vascular resistance.

Renal Natriuresis and Diuresis: ANP increases glomerular filtration rate by dilating afferent arterioles while constricting efferent arterioles, raising intraglomerular pressure. In the inner medullary collecting duct, cGMP inhibits epithelial sodium channels (ENaC) and amiloride-sensitive sodium transport, directly promoting natriuresis. ANP also inhibits sodium reabsorption in the proximal tubule and suppresses vasopressin-mediated water reabsorption by reducing aquaporin-2 insertion.

RAAS Inhibition: ANP suppresses renin release from juxtaglomerular cells through cGMP-mediated signaling, reducing angiotensin II and aldosterone production. ANP also directly inhibits aldosterone synthesis in adrenal zona glomerulosa cells by suppressing CYP11B2 (aldosterone synthase) expression.

Sympatholytic Effects: ANP reduces sympathetic nervous system activity through central and peripheral mechanisms, decreasing catecholamine release and heart rate. This contributes to blood pressure reduction and opposes the neurohormonal activation characteristic of heart failure.

Anti-inflammatory and Anti-fibrotic Actions: ANP/cGMP signaling inhibits NF-kappaB activation, reduces pro-inflammatory cytokine production, and suppresses cardiac fibroblast proliferation and collagen synthesis. These effects may contribute to long-term cardiovascular protection beyond hemodynamic modulation.

Reconstitution Calculator

Research

Safety Profile

ANP as an endogenous hormone has no intrinsic safety concerns. For carperitide (recombinant ANP), the primary adverse effect is dose-dependent hypotension, which is the most clinically significant limitation and can require dose reduction or discontinuation. Hypotension occurs because ANP acts on both the arterial and venous vasculature, reducing both preload and afterload. At recommended doses (0.0125-0.025 mcg/kg/min), significant hypotension occurs in approximately 5-10% of patients. Lower doses (0.0125 mcg/kg/min) are associated with fewer hypotensive episodes while maintaining hemodynamic efficacy. Other reported adverse effects include headache, nausea, and rare cases of bradycardia. Carperitide is contraindicated in patients with systolic blood pressure <90 mmHg, severe aortic or mitral stenosis, and cardiogenic shock. Renal function should be monitored during infusion, though carperitide is generally considered renal-protective at low doses.

Clinical Research Protocols

• Carperitide dosing (Japan — acute HF): 0.0125-0.025 mcg/kg/min continuous IV infusion. Ultra-low dose: 0.0125 mcg/kg/min. Standard dose: 0.025 mcg/kg/min. Maximum: 0.2 mcg/kg/min (rarely used). No loading bolus is standard practice. Duration typically 24-72 hours.
• ANP biomarker (MR-proANP): Acute HF diagnostic cutpoint: MR-proANP >120 pmol/L (BACH trial). Used for diagnosis and prognosis in acute dyspnea.
• Key trials: BACH (MR-proANP diagnosis), PROTECT (carperitide outcomes), TRUE-AHF (ularitide), PARADIGM-HF (neprilysin inhibition augmenting ANP), J-WIND (carperitide in acute MI).
• J-WIND trial: Evaluated carperitide in acute myocardial infarction; showed reduction in infarct size by approximately 14.7% but was underpowered for clinical endpoints (PMID: 17562884).

Subpopulation Research

• Hypertension: NPPA gene variants (rs5068, rs198358) are associated with lower blood pressure, reduced hypertension risk, and lower BNP levels, identifying ANP as a causal protective factor (PMID: 19412177).
• Atrial fibrillation: ANP is disproportionately elevated in AF due to atrial stretch and reduced atrial granule storage. ANP levels predict AF recurrence after cardioversion and ablation.
• Acute myocardial infarction: The J-WIND trial showed carperitide reduced infarct size by ~14.7% when administered during acute STEMI, suggesting direct cardioprotective effects (PMID: 17562884).
• Pregnancy/preeclampsia: ANP levels increase during normal pregnancy and are further elevated in preeclampsia. ANP may play a compensatory vasodilatory role against the hypertensive pathophysiology of preeclampsia.
• Obesity: Similar to BNP, ANP levels are paradoxically lower in obese individuals despite increased cardiovascular risk — the "natriuretic handicap" hypothesis. This deficiency may contribute to salt sensitivity, insulin resistance, and metabolic syndrome.
• Pediatric cardiac surgery: ANP levels predict hemodynamic instability and outcomes after pediatric congenital heart surgery.

Pharmacokinetic Profile

Ongoing & Future Research

• ANP augmentation for metabolic syndrome: Research into whether enhancing ANP signaling (through neprilysin inhibition or ANP analogs) can improve insulin sensitivity, fat metabolism, and metabolic syndrome components beyond cardiovascular effects.
• Designer natriuretic peptides: Engineering of chimeric peptides combining ANP/BNP sequences with enhanced receptor selectivity, reduced clearance, and improved pharmacokinetics (e.g., MANP — M-atrial natriuretic peptide).
• ANP gene therapy: Preclinical studies of AAV-mediated NPPA gene delivery for sustained ANP elevation in resistant hypertension.
• ANP and brown adipose tissue: ANP promotes brown adipose tissue thermogenesis through cGMP/PKG-mediated upregulation of UCP1, linking natriuretic peptides to energy expenditure and obesity treatment.
• Natriuretic peptide-based vaccines: Experimental approaches to generate antibodies against NPR-C (the clearance receptor) to reduce ANP/BNP degradation and enhance endogenous natriuretic peptide activity.
• ANP in cancer: Emerging evidence suggests ANP inhibits tumor growth, angiogenesis, and metastasis through NPR-A/cGMP signaling, with preclinical studies in lung, breast, and pancreatic cancer.